CD274 and hepatocellular carcinoma: All HCC samples were obtained from patients enrolled in two different clinical trials evaluating the effect of anti-CTLA4 (Tremelimumab; NCT02821754) or anti-CTLA4 plus anti-PD-L1 treatment (Durvalumab; NCT01853618) (13–15) which opened the possibility to study possible immune checkpoint inhibitor related changes in ILCs (Figure S1A).